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Journal of Stroke and CBackground: Impaired glucose tolerance is often present in patients with a transient
ischemic attack (TIA) or ischemic stroke and doubles the risk of recurrent stroke.
This impaired glucose tolerance can be transient, reflecting an acute stress response,
or persistent, representing undiagnosed impaired glucose metabolism possibly
requiring treatment. We aimed to assess the occurrence of persistent impaired
glucose tolerance after a stroke or TIA and to develop a prediction model to identify
patients at risk of persistent impaired glucose tolerance.Methods: Patients admitted
to the stroke unit or TIA clinic of the ErasmusMedical Centerwith ischemic stroke or
TIA and impaired glucose tolerance (2-hour postload glucose level of 7.8-
11.0 mmol/L) were consecutively enrolled between July 2009 and June 2012. The
oral glucose tolerance test was repeated after 3 months and patients were classified
as having transient impaired glucose tolerance or persistent impaired glucose toler-
ance. We developed a prediction model by means of a multivariable logistic regres-
sion model. We calculated the area under the receiver operating characteristic curve
(AUC) to quantify the performance of the model and the internal validity by boot-
strapping. Results: Of the 101 patients included, 53 (52%) had persistent impaired
glucose tolerance or progression to diabetes. These patients were older and more
often had hypertension and used statins. A prediction model including age, current
smoking, statin use, triglyceride, hypertension, previous ischemic cardiovascular
disease, body mass index, and fasting plasma glucose accurately predicted per-
sistent impaired glucose tolerance (bootstrappedAUC, .777), with statin use, triglyc-
eride, and fasting plasma glucose as the most important predictors. Conclusions:
Half of the patients with impaired glucose tolerance after a TIA or ischemic stroke
have persistent impaired glucose tolerance. We provide a prediction model to iden-
tify patients at risk of persistent impaired glucose tolerance, with statin use, triglyc-
eride, and fasting plasma glucose as the most important predictors, which after
external validation might be used to optimize secondary prevention. Key Words:
Stroke—TIA—impaired glucose tolerance—prediction model.
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S. FONVILLE ET AL.1670Introduction
Impaired glucose tolerance is an intermediate meta-
bolic state between normal glucose tolerance and diabetes
mellitus, and is present in more than one third of the
patients with a transient ischemic attack (TIA) or ischemic
stroke.1-10 This impaired glucose tolerance can be tran-
sient, reflecting an acute stress response, or persistent,
representing undiagnosed impaired glucose meta-
bolism.11,12 Various studies have found that impaired
glucose tolerance is still present after 3 months in
26%-71% of the patients.5-7 In patients with a TIA or
ischemic stroke, impaired glucose tolerance nearly
doubles the risk of recurrent stroke.13 It is therefore
important to identify patients with persistent impaired
glucose tolerance as they might benefit from long-term
lifestyle intervention and/or treatment with glucose-
lowering agents.14-16
We aimed to assess the occurrence of persistent
impaired glucose tolerance in nondiabetic patients with
an ischemic stroke or TIA. We developed a prediction
model to identify patients at risk of persistent impaired
glucose tolerance, based on clinical predictors available
at the time of admission.Methods
Study Population
Patients were derived from the Erasmus Stroke Study, a
prospective registry that started in 2005 and collects clin-
ical information and blood samples of all patients with
neurovascular diseases admitted to Erasmus University
Medical Center Rotterdam, The Netherlands. We pro-
spectively studied all consecutive patients with ischemic
stroke or TIA and impaired glucose tolerance (2-hour
postload glucose levels between 7.8 and 11.0 mmol/L)
admitted to the stroke unit or visiting our specialized
TIA clinic between July 2009 and June 2012within 2weeks
after symptom onset. Patients with pre-existent diabetes
and patients with 2-hour postload glucose levels of
11.1 mmol/L or higher (indicating newly diagnosed dia-
betes mellitus) were excluded. Written informed consent
was obtained from all patients signed by the participants
or a first-degree relative, as approved by the Institutional
Ethics Committee.Clinical Data
Demographic data, vascular history and risk factors
including statin use, laboratory assessments including
lipid profile, and data on event characteristics were
collected. Stroke severity was assessed with the National
Institutes of Health Stroke Scale score. Stroke subtype was
classified with the Trial of ORG 10172 in Acute Stroke
Therapy classification.17Glucose Assessments
In all patients, fasting plasma glucose and glycosylated
hemoglobin levels were assessed on the second or third
day of admission or when visiting the outpatient clinic,
as part of standard clinical care. On the same day, an
oral glucose tolerance test (OGTT) was performed accord-
ing to the World Health Organization protocol.18 After
overnight fasting, patients drank a solution of 75 g
glucose in 150 mL water, and 2-hour postload glucose
levels were assessed. Impaired glucose tolerance was
defined as 2-hour postload glucose levels between 7.8
and 11.0 mmol/L. Patients with fasting plasma glucose
levels of 7.0 mmol/L or higher were diagnosed with dia-
betes and therefore excluded.Outcome
At 3 months, all patients were invited to visit the outpa-
tient clinic and were asked to undergo a second OGTT.
The OGTTwas repeated and based on the results patients
were classified as having transient impaired glucose toler-
ance (2-hour postload glucose level of ,7.8 mmol/L),
persistent impaired glucose tolerance (2-hour postload
glucose level between 7.8 and 11.0 mmol/L), or pro-
gression to diabetes (2-hour postload glucose level of
$11.1 mmol/L).1Statistical Analysis
Statistical analyses were performed with Stata/SE 12.1
for Windows (Statacorp, College Station, TX). Missing
variables were imputed with single imputation using
the baseline characteristics and the outcome variable.
We compared clinical variables between glucose groups,
with transient impaired glucose tolerance as a reference.
Patients with persistent impaired glucose tolerance or
progression to diabetes were grouped together as persis-
tent disturbed glucose tolerance because of the small sam-
ple size. The differences between the glucose groups in
categorical variables were tested with the c2 test and
continuous variables with the Student t test. Non-
normal distributed variables were compared with the
Wilcoxon rank sum test. P values of less than .05 were
considered statistically significant.Model Development
Possible predictors of persistent impaired glucose toler-
ance included known risk factors for developing diabetes
and other risk factors according to the previous literature:
age, sex, ethnicity, current smoking, statin use, lipids
(triglycerides, low-density lipoprotein [LDL], and high-
density lipoprotein [HDL]), hypertension, previous
ischemic cardiovascular disease, atrial fibrillation (parox-
ysmal), body mass index (BMI), TIA versus ischemic
Table 1. Patient characteristics compared between patients with transient and persistent impaired glucose tolerance
Patient characteristics
Transient impaired glucose
tolerance (n 5 48)
Persistent impaired glucose
tolerance (n 5 53) P value
Age (y), mean (SD) 56 (14) 63 (14) .017
Male, n (%) 31 (65) 29 (55) .313
Caucasian, n (%) 43 (90) 45 (85) .483
Vascular risk factors
Current smoking, n (%) 18 (38) 11 (21) .063
BMI (kg/m2),* mean (SD) 26.6 (4.0) 27.6 (5.4) .305
Hypertension,y n (%) 17 (35) 35 (66) .002
Statin use, n (%) 6 (13) 21 (40) .002
Atrial fibrillation, n (%) 5 (10) 6 (11) .884
Vascular medical history
Ischemic cardiovascular disease, n (%) 8 (17) 16 (30) .111
Event characteristics
TIA, n (%) 17 (35) 20 (38) .809
Total NIHSS score, median (IQR)z 3 (1-6) 2 (1-4) .232
TOAST classification .885
Large artery disease, n (%) 6 (13) 5 (10)
Cardioembolism, n (%) 6 (13) 8 (15)
Small vessel disease, n (%) 17 (35) 15 (28)
Other, n (%) 2 (4) 2 (4)
Undetermined, n (%) 17 (35) 23 (43)
Glucose assessments during admission/visiting TIA clinic
Glucose on admission (mmol/L), mean (SD) 6.3 (1.3) 6.7 (1.6) .207
Fasting plasma glucose (mmol/L), mean (SD) 5.4 (.5) 5.5 (.6) .135
2-hour postload glucose (mmol/L), mean (SD) 8.9 (.8) 9.2 (.9) .165
Glycosylated hemoglobin (mmol/mol)/(%), mean (SD) 37 (3)/5.5 (.3) 39 (4)/5.7 (.4) .027
Days between event and OGTT, median (IQR) 3 (2-5) 2 (2-5) .333
Laboratory assessments during admission/visiting TIA clinic
Total cholesterol (mmol/L), mean (SD) 5.5 (1.1) 5.0 (1.2) .058
Triglycerides (mmol/L), mean (SD) 1.68 (.81) 1.43 (.58) .151
HDL (mmol/L), mean (SD) 1.32 (.45) 1.37 (.43) .611
LDL (mmol/L), mean (SD) 3.56 (1.04) 3.16 (1.07) .059
Abbreviations: BMI, body mass index; HDL, high-density lipoprotein; IQR, interquartile range; LDL, low-density lipoprotein; NIHSS,
National Institutes of Health Stroke Scale; OGTT, oral glucose tolerance test; SD, standard deviation; TIA, transient ischemic attack; TOAST,
Trial of ORG 10172 in Acute Stroke Therapy.
*Missing in 16 patients.
yDefined as the use of antihypertensive drugs before the event.
zInpatients with ischemic stroke only.
PERSISTENT IMPAIRED GLUCOSE TOLERANCE AFTER STROKE 1671stroke, large artery atherosclerosis, fasting plasma
glucose, 2-hour postload glucose, and glycosylated hemo-
globin levels.5-7,19 We graphically assessed the shape of
relationships between continuous predictors and
persistent impaired glucose tolerance with restricted
cubic spline functions. When the shape was nonlinear,
the variable was transformed according to the observed
relation. All potential predictors were tested with
univariable logistic regression analysis and those with P
value of .20 or less were further analyzed with a
multivariable logistic regression model, except for the
lipid variables. As the lipid variables are expected to be
correlated to statin use, they were first added separately
and subsequently simultaneously to the model. This
resulted in the basic model to which the glucose levels
were added to assess their additional prognostic value.On the basis of the 22 log likelihood of the models and
the P values of the corresponding c2, the best prediction
model was chosen. The discriminative ability of this
model (area under the receiver operating characteristic
curve [AUC]) was calculated. The AUC ranges from .50
for noninformative to 1.0 for perfect models. The
internal validity of the model was assessed by means of
bootstrapping techniques, resulting in an internally
validated AUC, which represents the expected perfor-
mance of the model in future patients.
Results
Study Population
Between July 2009 and June 2012, 1176 patients with a
TIA or ischemic stroke were admitted to the stroke unit
S. FONVILLE ET AL.1672or visited the outpatient clinic, and 236 of them had pre-
viously been diagnosed with diabetes mellitus. Of the
940 nondiabetic patients, 191 (20%) did not have an initial
OGTT, 357 (38%) had 2-hour postload glucose levels in
the normal range, 245 patients (26%) had impaired
glucose tolerance, and 147 (16%) had 2-hour postload
glucose levels in the diabetic range. Of the 245 patients
with initially impaired glucose tolerance, 98 patients
(40%) did not have a repeat OGTT, 31 (13%) had the initial
OGTT more than 2 weeks after the event, and 15 (6%)
were excluded because they did not have a fasting plasma
glucose or it was 7.0 mmol/L or higher. The remaining
101 patients with initially impaired glucose tolerance
and a repeat OGTT were analyzed in this study. The
OGTT was not repeated because of the follow-up in
another institution (general practitioner, other hospital,
or nursing home of residence) (16% of all patients), test
failed or refused by the patient (5%), no show (8%), event
before follow-up (deceased or recurrent stroke) (4%), or
lost-to-follow-up (7%). Patients who did not undergo a
second OGTT compared with those who did were signif-
icantly older (666 15 versus 606 15 years; P5 .010), and
were less often discharged to home (37% versus 79%;
P , .001).
Occurrence of Persistent Impaired Glucose Tolerance
Of the 101 patients, 47 (47%) had persistent impaired
glucose tolerance at 3 months and 6 (6%) had progressed
to diabetes. The patient characteristics are shown in
Table 1. Patients with persistent disturbed glucose toler-
ance were older and had more often hypertension and
statin use compared with those with transient impaired
glucose tolerance. Glycosylated hemoglobin levels were
significantly higher in these patients.Figure 1. Shape of relations between persistent impaired glucose tolerance and the
age, (B) fasting plasma glucose ($5.5 mmol/L), (C) 2-hour postload glucose, (D) gl
erides ($1.30 mmol/L), (G) LDL (#3.70 mmol/L), and (H) HDL (#1.60 mmol/L).
mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein.Prediction Model
The shape of relations between persistent impaired
glucose tolerance and the continuous variables with the
corresponding cutoff points are shown in Figure 1. Age
and 2-hour postload glucose levels had a linear relation
with persistent impaired glucose tolerance and were
analyzed as such. Glycosylated hemoglobin showed a
constant risk of less than 39 mmol/mol (,5.7%) and
values below that cutoff were truncated. The other
nonlinear variables (triglycerides, LDL, HDL, BMI, and
fasting plasma glucose) were all truncated in the same
way as glycosylated hemoglobin, with the corresponding
cutoff points shown in Figure 1.
On the basis of the results of the univariable regression
analysis (Table 2), the variables age, current smoking, hy-
pertension, previous cardiovascular disease, BMI, statin
use, triglycerides, LDL, fasting plasma glucose, 2-hour
postload glucose, and glycosylated hemoglobin levels
were selected for the prediction model. All variables
were further analyzed with a multivariable logistic
regression model, except for the 3 glucose variables. The
lipid variables (triglycerides and LDL) were added sepa-
rately to select the basic model. Adding triglycerides (if
,1.30 mmol/L, 1.30 mmol/L was used; model 2)
improved the model significantly (P 5 .043). However,
addition of LDL or both triglycerides and LDL, to the
model (models 3-4) did not improve the model signifi-
cantly (Table 3), so model 2 was chosen as the basic
model.
Addition of fasting plasma glucose (if ,5.6 mmol/L,
5.6 mmol/L was used; model 5) to the basic model signifi-
cantly improved the model (P 5 .024). The basic model
was not improved after entering 2-hour postload glucose
(model 6, P 5 .390) or glycosylated hemoglobin levelscontinuous variables with the corresponding cutoff points (dashed line): (A)
ycosylated hemoglobin ($39 mmol/mol), (E) BMI ($25 kg/m2), (F) triglyc-
Linear predictor (log odds) is shown on the y-axis. Abbreviations: BMI, body
Table 2. Selection of predictors for persistent disturbed glucose tolerance
Possible predictors OR (95% CI) P value
Age (per 10 y) 1.40 (1.05-1.88) .020
Male sex .66 (.30-1.48) .314
Caucasian .65 (.20-2.16) .485
Current smoking .44 (.18-1.06) .066
BMI (per kg/m2) (if ,25 kg/m2, 25 kg/m2 was used)* 1.13 (1.00-1.28) .054
Hypertension 3.55 (1.56-8.05) .002
Statin use 4.59 (1.66-12.70) .003
Atrial fibrillation 1.10 (.31-3.86) .884
Previous ischemic cardiovascular disease 2.16 (.83-5.64) .115
Ischemic stroke versus TIA .90 (.40-2.04) .809
Large artery atherosclerosis versus other causes .73 (.21-2.56) .622
Triglycerides (per mmol/L) (if ,1.30 mmol/L, 1.30 mmol/L was used)* .38 (.17-.86) .021
LDL (per mmol/L) (if $3.70 mmol/L, 3.70 mmol/L was used)* .53 (.29-.95) .033
HDL (per mmol/L) (if $1.60 mmol/L, 1.60 mmol/L was used)* 1.89 (.50-7.19) .351
Fasting plasma glucose (per mmol/L) (if ,5.6 mmol/L, 5.6 mmol/L was used)* 6.37 (1.16-35.08) .033
2-hour postload glucose (per mmol/L) 1.40 (.87-2.23) .165
Glycosylated hemoglobin (per mmol/mol) (if ,39 mmol/L, 39 mmol/L was used)* 1.31 (.98-1.76) .064
Abbreviations: BMI, body mass index; CI, confidence interval; HDL, high-density lipoprotein; LDL, low-density lipoprotein; OR, odds ratio;
TIA, transient ischemic attack.
Possible predictors with P value of .2 or less were included in the multivariable logistic regression analysis.
*Cutoff point based on Figure 1.
PERSISTENT IMPAIRED GLUCOSE TOLERANCE AFTER STROKE 1673(model 7, P 5 .059) (Table 3). Model 5 was therefore cho-
sen as the final prediction model, with a good discrimina-
tive disability of .805. The internally validated AUC was
.777, indicating good performance. The strongest predic-
tors in the model were the presence of statin use (adjusted
odds ratio [OR] 4.74; 95% confidence interval [CI], 1.24-
18.01), triglycerides (adjusted OR, .39; 95% CI, .16-.96),
and fasting plasma glucose (adjusted OR, 8.97; 95% CI,
1.19-67.70). The risk of persistent impaired glucose toler-Table 3. Selection of the best basic model and th
Model Variables
1 Age, current smoking, hypertension, previo
cardiovascular disease, BMI, and statin u
Addition of lipid variables to model
2 Model 1 1 triglycerides (per mmol/L)*
3 Model 1 1 LDL (per mmol/L)z
4 Model 1 1 triglycerides 1 LDL
Added value of glucose test to model
5 Model 2 1 fasting plasma glucose (per mm
6 Model 2 1 2-hour postload glucose (per m
7 Model 2 1 glycosylated hemoglobin (per m
Abbreviations: BMI, body mass index; LDL, low-density lipoprotein.
*If triglycerides were ,1.30 mmol/L, 1.30 mmol/L was used.
yCompared with model 1.
zIf LDL was $1.60 mmol/L, 1.60 mmol/L was used.
xIf fasting plasma glucose was less than 5.6 mmol/L, 5.6 mmol/L was
jjCompared with model 2.
{If glycosylated hemoglobin was less than 39 mmol/mol, 39 mmol/moance after a TIA or stroke for individual patients can be
calculated with the formula shown below Table 4.Discussion
This study showed that approximately half of the pa-
tients with a TIA or ischemic stroke and impaired glucose
tolerance had persistent disturbed glucose tolerance
after 3 months. We developed a prediction model thate added value of glucose tests to the model
c2 P value
us ischemic
se
21.40 Reference
25.48 .043y
23.84 .118y
26.64 .073y
ol/L)x 30.56 .024jj
mol/L) 26.22 .390jj
mol/mol){ 29.06 .059jj
used.
l was used.
Table 4. Final prediction model to assess the risk of
persistent disturbed glucose tolerance
Predictor aOR (95% CI)
Age (per 10 y) 1.18 (.79-1.77)
Current smoking .74 (.23-2.37)
Statin use 4.74 (1.24-18.01)
Triglycerides (per mmol/L) .39 (.16-.96)
Hypertension 2.14 (.76-6.01)
Previous ischemic cardiovascular
disease
.48 (.12-2.03)
BMI (per kg/m2) 1.12 (.98-1.28)
Fasting plasma glucose (per mmol/L) 8.97 (1.19-67.70)
Abbreviations: BMI, body mass index; CI, confidence interval;
aOR, adjusted odds ratio.
Risk of persistent disturbed glucose tolerance: exp(linear predic-
tor)/(1 1 exp[linear predictor]). Linear predictor 5 215.607 1
0.017 3 age 2 0.308 3 current smoking 1 1.555 3 statin use 2
0.934 3 triglycerides 1 0.763 3 hypertension - 0.726 3 previous
ischemic cardiovascular disease2 0.1153 BMI1 2.1943 fasting
plasma glucose. If triglycerides are less than 1.30 mmol/L, use
1.30 mmol/L, if BMI is less than 25 kg/m2, use 25 kg/m2, and if fast-
ing plasma glucose is less than 5.6 mmol/L, use 5.6 mmol/L.
AUC 5 .805, bootstrapped mean AUC 5 .777.
S. FONVILLE ET AL.1674accurately predicts persistent impaired glucose tolerance
(bootstrapped AUC, .777) using age, current smoking, hy-
pertension, previous ischemic cardiovascular disease,
BMI, statin use, triglycerides, and fasting plasma glucose,
clinical variables readily available on admission. The
strongest predictors for persistent impaired glucose meta-
bolism at 3 months were statin use, triglycerides, and fast-
ing plasma glucose.
To our knowledge, only 3 studies repeated the OGTT
3 months after discharge to investigate the persistence of
disturbed glucose tolerance after an ischemic stroke.5-7
Persistent disturbed glucose tolerance was present in
26%-71% of the patients with 4%-42% progressing to
diabetes.5-7 Two of these studies found that the 2-hour
postload glucose level was a predictor for persistent
disturbed glucose tolerance,6,7 which is in contrast to our
results. This may be because of the small sample size
and different statistical analysis methods of these studies.
Impaired fasting glucose and impairedglucose tolerance
have different pathophysiological mechanisms: hepatic
versus muscle insulin resistance. However, they often
coexist indicating more advanced disease and an even
higher risk of developing diabetes comparedwith patients
with impaired fasting glucose or impaired glucose toler-
ance alone.20,21 Dyslipidemia is often present in patients
with impaired fasting glucose and/or impaired glucose
tolerance. This corresponds to the importance of fasting
plasma glucose, triglyceride levels, and the presence
of statin use in predicting persistent impaired glucose
tolerance.19
Strengths of our study are the prospective design and
the relative large number of cases. Our study has alsosome limitations. The OGTT was not repeated in 49% of
the patients. As these patients were older, and were less
often discharged to home, this affects generalizability of
our findings. Because we did not include all patients
with a TIA or ischemic stroke admitted to our hospital
in our study, we are not able to estimate the prevalence
of persistent impaired glucose tolerance in the total stroke
population. However, based on data from our center we
estimate that approximately 20% of all patients have
pre-existing diabetes. From our study, we have learned
that 33% of the nondiabetic patients have impaired
glucose tolerance, and about half had persistent impaired
glucose tolerance or progression to diabetes.
Furthermore, this was an observational study and was
thus hampered by important missing data. We used
imputation to overcome the problem of missing values,
which is preferred over complete case analysis.22 Of
course, our model should be externally validated in an in-
dependent comparable population before its use in clin-
ical practice can be recommended.
Our study confirms the hypothesis that disturbed
glucose metabolism in the acute phase is not only because
of a stress reaction, but might also indicate underlying un-
diagnosed disturbed glucose metabolism. As impaired
glucose tolerance is often present after a TIA or stroke,
predicting the persistence of impaired glucose tolerance
is very important. These patients do not only have an
increased risk of developing diabetes but also an
increased risk of recurrent events. Intensive lifestyle inter-
vention and/or antidiabetic drug therapy can be started
directly after the TIA or stroke in the patients with high
risk of persistent impaired glucose tolerance in the
context of secondary stroke prevention. The treatment
of impaired glucose tolerance after a TIA or stroke is still
subject of several trials. The Metformin and sitAgliptin in
patients with impAired glucose tolerance and a recent
TIA or minor ischemic Stroke (MAAS) trial (http://
www.trialregister.nl/trialreg/admin/rctview.asp?TC53196)
is a phase II trial currently investigating the feasibility and
safety of both metformin and sitagliptin in patients with
impaired glucose tolerance after a TIA or ischemic
stroke. The Insulin Resistance Intervention after
Stroke (IRIS) trial (http://clinicaltrials.gov/ct2/show/
NCT00091949) is a phase III trial investigating the effect
of treatment with thiazolidinedione drugs on the occur-
rence of recurrent stroke in patients with a recent TIA
or ischemic stroke and insulin resistance.Conclusions
To sum up, half of the patients with impaired glucose
tolerance after a TIA or ischemic stroke have persistent
impaired glucose tolerance. We provide a prediction
model to identify patients at risk of persistent impaired
glucose tolerance, with statin use, triglyceride, and fast-
ing plasma glucose as the most important predictors,
PERSISTENT IMPAIRED GLUCOSE TOLERANCE AFTER STROKE 1675which after external validation might be used to optimize
secondary prevention.References
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